With almost every aspect of pharmaceutical regulation currently under review across Europe and the proposal for changes expected in December 2022, in this article, Maarten Meulenbelt, Partner at Sidley Austin LLP, discusses with European Pharmaceutical Review some of the more controversial amendments under consideration and emphasises why industry participation is critical at this stage of the proposal discussions.
2022 is probably the biggest year in EU pharmaceutical law that I have seen in 30 years. It is an exciting year… but whether the changes will be a net positive or a net negative is yet to be seen” Maarten Meulenbelt, Partner, Sidley Austin LLP
2022 is undeniably a critical year for change in the pharmaceutical industry: for the first time in several decades, the European Union (EU)’s pharmaceutical legislation is up for review. This means numerous key aspects of how pharmaceuticals are regulated in the EU could be affected, from costing and reimbursement to intellectual property rights, incentives and more.
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. These events led to the publication of the EU Pharmaceuticals Strategy in 2020,1 which, in addition to a range of other activities, aims to ensure the regulatory system for human medicines is future‑proof and crisis-resistant. To this end, the strategy lays out a timeline for review of the EU’s general legislation on medicines for human use.
Following initial consultations in 2021, we expect the publication of the proposal for changes to the EU’s pharmaceutical legislation and potential adoption by the European Commission (EC) by December 2022. But what are the key potential changes and how could they impact drug developers and manufacturers?
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Maarten Meulenbelt, a Sidley Austin LLP Partner focused on EU regulatory affairs, litigation and competition law, explained that four key pieces of pharmaceutical legislation are likely to be affected by the proposals – namely Directive 2001/832 and Regulation 726/20043 (together called the “EU general pharmaceuticals legislation”) and the Orphan Regulation4 and Paediatric Regulation.5,6
One of the key priorities of the EU’s strategy is to encourage innovation to solve unmet medical needs. “The Commission has stated that for 90 percent of the thousands of orphan diseases there are no specific treatment options – only best available care. The Commission is looking at how we can direct some investment to these areas of high unmet need,” stated Meulenbelt.
He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Although how ‘unmet need’ will be defined is yet to be ascertained.
Conditionality of intellectual property
There are several potentially controversial incentives that have been mentioned to enhance access to medicine and overcome unmet medical need, including conditionality of intellectual property (IP) rights. Under the conditional system, Meulenbelt explained, companies might obtain and maintain their IP rights based on a series of conditions. Two conditions under consideration are that companies must launch the product in most, if not all, EU Member States; and that R&D expenditure must be transparently reported.
at this stage of the discussions, it is critical that industry stakeholders share their insights and experience, whether directly or through trade associations”
Both conditions are far reaching and create additional risk for companies to launch products – particularly orphan medicinal products (OMPs) – in the EU.
What are the implications of launching in all States? Meulenbelt highlighted “the desire to have broader launches is very good,” since under the current model, if OMP companies can make a major part of their sales in a limited number of markets they are unlikely to launch elsewhere, limiting patient access.
Most companies are initially focused on the big five markets in Europe (Germany, France, Italy, Spain and the UK). By incentivising broader launches, companies will need to consider markets they may not have previously focused on, and engage with stakeholders in those broader markets to help them launch a product.
However, a concern is that the EU has no power to regulate what Member States will pay for medications, so if companies are forced to launch everywhere, this may include countries with limited funding for drugs. “If you have to launch a drug at a low price, obviously that affects your overall business case significantly,” remarked Meulenbelt.
Transparently reporting R&D expenditure could also be a massive threat to the industry by revealing confidential trade secrets, confounded by the lack of agreed standards on what should be included in the cost. “If we concentrate on cost, EU governments like to focus on out-of-pocket expenses for costing R&D, for example, the amount of money you pay a contract research organisation to conduct a clinical trial for your product. However, a Gupta study from 2019 on what companies spend money on when developing new drugs showed that out‑of‑pocket expenses account for only seven percent of the overall cost of developing drugs.7 A further 40 percent is the cost of failure – the drugs that never make it to market – and the final 53 percent is the cost of capital,” explained Meulenbelt. As a result, the risk of failure is particularly high in the drug development industry.
Stakeholders in the EU often use the risk-adjusted Net Present Value (rNPV) investment model to determine whether to invest in a pharmaceutical product. The outcome of that model can be used to compare the value with investments in other industries, from automotive to aeronautical, he stated. rNPV uses several key figures, including expected earnings, length of time for return on investment and the risks of failure, to derive a figure. NPV can also be used to calculate what is called the ‘minimum viable price’ for a product.
Calculating a minimum viable price based on out-of-pocket expenses, just seven percent of the overall R&D costs, versus one hundred percent can create prices with 10-factors of difference, stated Meulenbelt. Thus, if you only take into account the costs, you may not be able to achieve a viable price that fully reflects the risks and probabilities of achieving clinical success and market access for the product.
Risks of limiting orphan drug incentives
Meulenbelt pointed to two economic studies evaluating the potential impact of removing or limiting the incentives for orphan drugs: the first from the UK’s Office of Health Economics (OHE)8 and the second commissioned by the European Federation of Pharmaceutical Industry Associations (EFPIA) and published by Dolon.9
The OHE report found that the existing Orphan Drug Regulation, which provides research grants and protocol assistance to promote innovation and market exclusivity to heighten potential economic returns, has successfully incentivised companies to invest in the development of OMPs.8 Under the current scenario, rNPV for investment in most cases is positive. By modelling different change proposals, they found lowering market exclusivity by two years had a negative impact on the rNPV, though it did remain positive; however, lowering the market exclusivity in addition to removing protocol assistance resulted in a negative rNPV. “This suggests that any of the modelled changes to the regulation could lead to a decrease in the number of OMPs developed… Some of the assessed changes to the regulation could undermine the business model under which OMP‑focused companies operate, and… it would also no longer be more rational for broader-portfolio companies to prioritise investments in (some) OMPs relative to other products,” wrote the authors.
The Dolon report found that over half (74) of the 142 OMPs developed between 2000 and 2017 would not have been economically viable in the absence of the existing regulation.9
In both cases, the reports caution what could be damaged by reducing the protections for OMPs that are set out in the Orphan Drug Regulation. The OMP market is currently growing at twice the rate of the non-orphan market,10 reflecting tremendous progress for key areas of unmet need, and it would be a shame to see this halted.
Reducing market exclusivity
Another potential incentive under consideration to combat unmet medical need and encourage broader patient access is reducing market exclusivity for OMPs.
“Currently you can get 10 years of market exclusivity for orphan drug products. This is a limited type of exclusivity; it does not protect you against a better product, but it does safeguard against a similar product for the same indication being submitted for approval. Additionally, if your product works in two completely different indications, you can get a second or even a third orphan exclusivity. This helps stimulate investment in new indications,” explained Meulenbelt.
The EC is considering reducing the market exclusivity for new indications and hypothetically giving orphan exclusivity only to products defined as addressing unmet needs. If the probability of attaining an orphan drug designation decreases, it could affect whether companies are willing to invest in that orphan space.
Reimbursement
A trend in some Member States is for drug products to be reimbursed based on competitor products, including those that are not authorised. “The trend that we see starting now, is for some Member States to claim that the reimbursement of a drug should not be linked to the value of the product or even the cost of the product, but the cost of the replacement product,” stated Meulenbelt.
This could mean that reimbursement for a complex product, such as a cell and gene therapy, could be based on that of a ‘compounded’ version of the product (produced using ‘bedside manufacturing’), and reimbursement for chemical drugs could be based on pharmacy-compounded oral solid dosage form and other products for the same indication that have no form of regulatory approval. “This obviously presents a huge magnitude of risk for drug developers,” he noted.
Future outlook
changes such as introducing the conditionality of IP rights or the obligation to disclose R&D costs will likely have an immediate impact on decision-making within companies”
The proposal for the changes is anticipated in December 2022, at which point it will go through the legislative process of the European Parliament and the Council Of Ministers before finally being accepted. But what is the timescale for this process?
“The speed of EU law has become less predictable; however, we are talking about the biggest change to EU law since 1965 by a wide margin, since many of the basic concepts are up for re-evaluation. It is a massive change that is likely to take at least one or two years of very intensive discussions between the institutions and the stakeholders to accept.
“The actual legislation will then have a certain implementation period and will be prospective, for the most part. So, the actual effect in law may be several years away,” explained Meulenbelt.
However, he noted that changes such as introducing the conditionality of IP rights or the obligation to disclose R&D costs will likely have an immediate impact on decision-making within companies.
Conclusions
Whether the changes to the EU’s Pharmaceutical Legislation will achieve the aims of supporting patient access, encouraging innovation to overcome unmet medical need, and settling drug pricing concerns is yet to be seen, according to Meulenbelt. “It is too early to say because we have not seen the whole package of measures yet. It is also possible that, whether it is a net positive or a net negative will be largely dependent on what segment of the market you are in,” he stated.
Take paediatrics, for instance: the EC is considering requiring more paediatric studies, since the mechanisms of action of a drug designed for adults might also be beneficial in certain unrelated conditions occurring in children. However, despite the potential benefits of creating a wider range of treatment options, where these trials are not feasible or in an area that the company does not understand, paediatric studies could be a significant burden, especially for smaller organisations. Drug manufacturers, on the other hand, are likely to benefit from the incentives to strengthen the resilience of the supply chain on the continent laid out by the EU Pharmaceutical Strategy.
He concluded that, at this stage of the discussions, it is critical that industry stakeholders share their insights and experience, whether directly or through trade associations, to ensure that the resulting legislation is not only coherent but also beneficial: “Specialised members of the industry must be properly involved in the discussions, because if they fail to do it this year, they will have to wait a very long time for another opportunity.”
Maarten Meulenbelt is a Sidley Austin LLP Partner. He focuses his practice on EU regulatory affairs, litigation and competition law issues affecting the life sciences sector in Europe. In addition to advising on EU life sciences matters, Maarten also handles competition litigation at the EU and national levels. He has extensive litigation experience before the EU Courts, national courts and competition authorities, the European Commission, and national regulatory authorities in several EU Member States. Maarten has significant competition law experience in a variety of sectors.
About the author
Hannah Balfour is the Science Writer for European Pharmaceutical Review.
References
European Commission. COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS Pharmaceutical Strategy for Europe. Brussels; 2020.
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2022.
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance). THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2004.
Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2000.
Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance). THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2006.
Regulation (EC) No 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use (Text with EEA relevance). THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2006.
Berdud M, Garau M, O’Neill P, et al. Economic and Financial Challenges of Developing Orphan Medicinal Products. Does the European Legislation Tackle Them? OHE Consulting Report [Internet]. London: Office of Health Economics; 2020. Available from: https://www.eucope.org/wp-content/uploads/2020/04/ohe…
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.